ERBB2 and metastatic malignant neoplasm in the lymph nodes: The following 8 variables were assessed: HR status (positive versus negative), ET (yes versus no), age (years), clinical stage at diagnosis (IIA, IIB, or IIIA versus IIIB or IIIC), histological grade (1 or 2 versus 3), HER2 status (positive versus negative), clinical response (CR versus PR versus SD or PD), and the number of lymph node metastases (0 versus 1–3 versus ≥4).